Adenocarcinoma of prostate

Drago JR, Badalament RA, Wientjes MG, Smith JJ, Nesbitt JA, York JP, Ashton JJ, Neff JC. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate Ohio State University experience. Urology 1989 34 187-92. 

Neoplasms that are essentially negative with most CEA antibodies include adenocarcinomas of prostate, kidney, adrenal gland, and endometrium,220 along with serous ovarian tumors and mesotheliomas. Liver cell-derived tumors are nonreacti ve with the monoclonal CEA antibodies but do react with the polyclonal antibodies... 

Seeni A, Takahashi S, Takeshita K, Tang M, Sugiura S, Sato SY, Shirai T (2008) Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev 9 7-14... 

The normal prostate is composed of acinar secretory cells arranged in a radial shape and surrounded by a foundation of supporting tissue. The size, shape, or presence of acini are almost always altered in the gland that has been invaded by prostatic carcinoma. Adenocarcinoma, the major pathologic cell type, accounts for more than 95% of prostate cancer cases.15 Much rarer tumor types include small cell neuroendocrine cancers, sarcomas, and transitional cell carcinomas. 

Tables 8 and 9 show how some of the previously mentioned antibodies can distinguish between metastatic adenocarcinomas of unknown primaries in females and males, respectively. The panels are similar except for ERP (estrogen receptor protein), GCDFP-15, and S-100, which are used in females for their specificity for gynecologic tumors and PSA (prostatic specific antigen), used in males for its specificity for prostatic adenocarcinoma. These antibodies cannot absolutely distinguish among the tumor sources listed. However, they can guide pathologists and clinicians on which organs need to be further examined to determine the primary source of a metastatic tumor.

Detection/staging/ follow-up of prostate adenocarcinoma Prevention of blood clots... 

Adenocarcinoma of the prostate is one of the most common malignant tumors in adult males. For advanced disease palliative hormonal therapy has been... 

Doxorubicin is one of the most effective agents used in the treatment of carcinomas of the breast, ovary, endometrium, bladder, and thyroid and in oat cell cancer of the lung. It is included in several combination regimens for diffuse lymphomas and Hodgkin s disease. Doxorubicin can be used as an alternative to daunorubicin in acute leukemias and is useful in Ewing s sarcoma, osteogenic sarcoma, soft-tissue sarcomas, and neuroblastoma. Some activity has been reported in non-oat cell lung cancer, multiple myeloma, and adenocarcinomas of the stomach, prostate, and testis. 

Prostatic Adenocarcinoma. For prostatic adenocarcinomas, their typical slow growth rate and low cycling fraction provide a logical radiobiological rationale for exploring neutrons (high LET) in the treatment of this disease. 

Shain, S.A., McCullough, B and Nitchuk, W.M. (1979). "Primary and transplantable adenocarcinomas of the AxC rat ventral prostate morphologic characterization and examination of Cu-steroid metabolism by early passage tumors, J. Natl. Cancer Inst. 62,313. 

Tay M-H, Kaufman DS, Regan MM, Leibowitz SB, George DJ, Febbo PG, Manola J, Smith MR, Kaplan ID, Kantoff PW, Oh WK. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate Ann Oncol 2004 15 974-8. 

The relation between androgens and crythropoiesis is well known. In 42 patients with adenocarcinoma of the prostate, leuprolide acetate and flutamide (an antiandrogen) were used in combination (36). Hemoglobin concentrations fell by more than 25% in six patients who developed symptomatic anemia. Checking the hemoglobin at 3 months was thought to be useful in predicting those who would become symptomatic. 

Hormonal therapy with testosterone should be reserved primarily for patients with hypogonadal disorders. There are two important warnings about the indiscriminate use of intramuscular testosterone in patients with serum testosterone levels in the normal range. First, many impotent patients are older and may have adenocarcinoma of the prostate, thus exogenous testosterone may accelerate the growth of the neoplasm. Second, although testosterone may induce a marked increase in libido, patients may still be unable to achieve adequate erection. 

N10. Noble, R. L., The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res. 37, 1929-1933 (1977). 

B6. Bissada, N. K., and Kaczmarek, A. T., Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of dietylstilbestrol. J. Urol. 153, 1944-1945 (1995). 

D19. Dionne, C. A., Camoratto, A. M., Jani, J. P., Emerson, E., Neff, N., etal., Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin. Cancer Res. 4,1887-1898 (1998). 

M33. Myers, R. B., Kudlow, J. E., and Grizzle, W. E., Expression of transforming growth factor a, epidermal growth factor and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia. Mod. Pathol. 6,733-737 (1993). 

Foster, B. A., Gingrich, J. R., Kwon, E. D., Madias, C. and Greenberg, N. M. (1997). Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 57, 3325-3330. 

---